Del. HC Stresses Mandatory Legal Assistance to Preserve Fairness and Integrity of Criminal Trials || Supreme Court: Delhi High Court Ruling upheld on Taekwondo National Sports Federation Recognition || SC: Blockchain-Based Digitisation of Land Records Necessary to Reduce Property Document Litigation || Supreme Court to NCLT : Limit Power to Decide Intellectual Property Title Disputes under IBC || Bombay HC: Railway Employee With Valid Privilege Pass is Bona Fide Passenger Despite Missing Entries || Delhi High Court: Mere Pleadings Made To Prosecute or Defend a Case Do Not Amount To Defamation || Delhi High Court: Asking an Accused To Cross-Examine a Witness Without Legal Aid Vitiates The Trial || Delhi High Court: Recruitment Notice Error Creates No Appointment Right Without Vacancy || Supreme Court: Subordinate Legislation Takes Effect Only From its Publication in The Official Gazette || Supreme Court: DDA Must Adopt a Litigation Policy To Screen Cases and Avoid Unnecessary Filings

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :